We use cookies to help us improve your browsing experience and understand how people use our website. Our privacy statement explains how we use cookies, and how to change your cookie settings.


Galapagos’ mission is to develop first-in-class medicines with block buster potential based on the discovery of novel targets. Galapagos researchers have gone from target to proof of concept in three lead programs addressing broad disease categories affecting millions worldwide. 

Using human primary cells and patient cells, the company discovers which proteins (‘targets’) play a key role in causing diseases such as rheumatoid arthritis, inflammatory bowel disease and fibrosis. Galapagos then aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease. This approach addresses the disease itself rather than just treating the symptoms.

Galapagos' aim is to make a lasting positive contribution to society through discovery of breakthrough therapies for diseases with large unmet need. 

Related publications

Quantification Assays for Total and Polyglutamine-Expanded Huntingtin Proteins
Douglas Macdonald, Michela A. Tessari, Ivette Boogaard, Melanie Smith, Kristiina Pulli, Agnieszka Szynol, Faywell Albertus, Marieke B. A. C. Lamers, Sipke Dijkstra, Daniel Kordt, Wolfgang Reindl, Frank Herrmann, George McAllister, David F. Fischer, Ignacio Munoz-Sanjuan
PLoS ONE 9(5): e96854. doi:10.1371/journal.pone.0096854

Biology calls the targets: combining RNAi and disease biology
van Es H, Arts GJ
Drug Discov Today 2005 Oct 15;10(20):1385-91

Functional screening of viral siRNA libraries in human primary cells
Bortone K, Michiels F, Vandeghinste N, Tomme P, and van Es H.
Drug Discov World 2004 Fall:20-27

Adenoviral vectors expressing siRNAs for discovery and validation of gene function
Arts GJ, Langemeijer E, Tissingh R, Ma L, Pavliska H, Dokic K, Dooijes R, Mesic E, Clasen R, Michiels F, van der Schueren J, Lambrecht M, Herman S, Brys R, Thys K, Hoffmann M, Tomme P, van Es H
Genome Res. 2003 Oct;13(10):2325-32

Arrayed adenoviral expression libraries for functional screening
Michiels F, van Es H, van Rompaey L, Merchiers P, Francken B, Pittois K, van der Schueren J, Brys R, Vandersmissen J, Beirinckx F, Herman S, Dokic K, Klaassen H, Narinx E, Hagers A, Laenen W, Piest I, Pavliska H, Rombout Y, Langemeijer E, Ma L, Schipper C, Raeymaeker MD, Schweicher S, Jans M, van Beeck K, Tsang IR, van de Stolpe O, Tomme P, Arts GJ, Donker J
Nat Biotechnol. 2002 Nov;20(11):1154-7. Erratum in: Nat Biotechnol. 2003 Feb;21(2):199